NCT01580618View on ClinicalTrials.gov

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Pleural Effusion
Interventions
DRUG

normal saline

Injection of 60 ml normal saline twice a day for three days using the existing chest tube.

DRUG

TNK (Tenecteplase)

Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.

Trial Locations (1)

96819

Kaiser Foundation Hospital, Honolulu

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Kaiser Permanente

OTHER